↓ Skip to main content

Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options

Overview of attention for article published in BMC Cancer, February 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

blogs
1 blog
twitter
2 X users

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
29 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options
Published in
BMC Cancer, February 2018
DOI 10.1186/s12885-018-4101-7
Pubmed ID
Authors

Peter F. McAnena, Andrew McGuire, A. Ramli, C. Curran, C. Malone, R. McLaughlin, K. Barry, James A.L. Brown, M. J. Kerin

Abstract

Recent studies have shown that breast cancer subtype can change from the primary tumour to the recurrence. Discordance between primary and recurrent breast cancer has implications for further treatment and ultimately prognosis. The aim of the study was to determine the rate of change between primary and recurrence of breast cancer and to assess the impact of these changes on survival and potential treatment options. Patient demographics were collected on those who underwent surgery for breast cancer between 2001 and 2014 and had a recurrence with biopsy results and pathology scoring of both the primary and recurrence. One hundred thirty two consecutive patients were included. There were 31 (23.5%) changes in subtype. Discordance occurred most frequently in luminal A breast cancer (n = 20), followed by triple negative (n = 4), luminal B (n = 3) and HER2 (n = 3). Patients who changed from luminal A to triple negative (n = 18) had a significantly worse post-recurrence survival (p < 0.05) with overall survival approaching significance (p = 0.064) compared to concordant luminal A cases (n = 46). Overall receptor discordance rates were: estrogen receptor 20.4% (n = 27), progesterone receptor 37.7% (n = 50) and HER2 3% (n = 4). Loss of estrogen receptor and progesterone receptor was more common than gain (21 vs. 6 (p = 0.04) and 44 vs. 6 (p = 0.01) respectively). Nine patients (6.8%) gained receptor status potentially impacting treatment options. Discordance in subtype and receptor status occurs between primary and recurrent breast cancer, ultimately affecting survival and potentially impacting treatment options.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 29 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 17%
Other 4 14%
Researcher 4 14%
Lecturer 2 7%
Student > Bachelor 1 3%
Other 2 7%
Unknown 11 38%
Readers by discipline Count As %
Medicine and Dentistry 10 34%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Computer Science 2 7%
Nursing and Health Professions 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 1 3%
Unknown 12 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2022.
All research outputs
#3,747,623
of 23,299,593 outputs
Outputs from BMC Cancer
#879
of 8,438 outputs
Outputs of similar age
#74,090
of 331,803 outputs
Outputs of similar age from BMC Cancer
#38
of 223 outputs
Altmetric has tracked 23,299,593 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,438 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,803 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 223 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.